Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/34584

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34584

Title:	Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study
Authors:	Hong, Chon-Seng Chen, Yi-Chen Ho, Chung-Han Hsieh, Kun-Lin Chen, Michael Shih, Jhih-Yuan Chiang, Chun-Yen Chen, Zhih-Cherng Chang, Wei-Ting
Contributors:	Chi Mei Hospital Chi Mei Hospital Southern Taiwan University of Science & Technology Chi Mei Hospital National Cheng Kung University Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Chung Hua University Southern Taiwan University of Science & Technology National Cheng Kung University
Keywords:	androgen-deprivation therapy risk epidemiology thrombosis agonists disease statins taiwan stroke men
Date:	2022
Issue Date:	2023-12-11 13:59:08 (UTC+8)
Publisher:	FRONTIERS MEDIA SA
Abstract:	Although androgen deprivation therapy (ADT) has been proposed to be associated with a higher risk of venous thromboembolisms (VTEs), whether gonadotropin-releasing hormones (GnRHs), such as both agonists and antagonists, are also associated with VTEs remain unclear. Using the Taiwan Cancer Registry (TCR) linked with the National Health Insurance Research Database, we identified patients diagnosed with prostate cancer from 2008 to 2015. Patients who received GnRH were 1:1 propensity score matched with non-GnRH users by age and cancer stage at diagnosis and clinical stage. Cox regression analysis was applied to estimate the incidences of VTEs with death as a competing event at the 5-year follow-up. The VTE incidence among GnRH users was 1.13% compared with 0.98% among non-users. After adjusting with potential confounding factors, the risk of VTEs showed borderline statistical significance among GnRH users and non-users. Notably, in the subgroup analysis among patients receiving GnRH therapy, those younger than 70 years old or at an earlier stage (stage I/II) were at a higher risk of VTEs. Different from previous studies, our findings highlighted critical concerns regarding the cardiac safety of GnRH therapies in prostate cancer patients at a relatively younger age or at an earlier stage.
Relation:	FRONTIERS IN CARDIOVASCULAR MEDICINE, v.9
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
cvm.2022.794310.pdf		504Kb	Adobe PDF	108	View/Open
index.html		0Kb	HTML	287	View/Open

Loading...